Reltecimod (AB-103) TFA is an antagonist of the T-cell-specific surface glycoprotein CD28 (TP44), demonstrating efficacy against various bacterial infections, including their exotoxins and endotoxins, as well as ionizing radiation. By modulating the inflammatory response through attenuation of the key CD28/B7-2 co-stimulatory pathway without full inhibition, Reltecimod TFA is utilized in researching necrotizing soft-tissue infections (NSTIs) [1].

Reltecimod（剂量范围1.25-5 mg/kg；静脉注射）TFA 能够有效提升感染多种细菌的小鼠存活率[1]。